Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Budesonide + triamcinolone is a combination of two synthetic corticosteroids, each with potent anti-inflammatory and immunosuppressive properties. Budesonide is primarily used to treat inflammatory diseases affecting the airways and gastrointestinal tract, such as asthma, COPD, Crohn's disease, and ulcerative colitis[1][3][6]. Triamcinolone is used for a wide range of inflammatory conditions including allergic disorders, arthritis, skin diseases, ocular inflammation, and certain autoimmune conditions[4][8]. Both drugs act by binding to the glucocorticoid receptor and modulating gene expression to suppress pro-inflammatory cytokines and mediators. The combination would theoretically provide additive or synergistic anti-inflammatory effects but is not a standard or widely marketed fixed-dose product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on budesonide + triamcinolone.